• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Surgical resection for hilar cholangiocarcinoma: experience improves resectability.肝门部胆管癌的外科切除术:经验可提高可切除性。
HPB (Oxford). 2012 Feb;14(2):142-9. doi: 10.1111/j.1477-2574.2011.00419.x. Epub 2011 Dec 12.
2
[Surgical therapy of hilar cholangiocarcinoma].[肝门部胆管癌的外科治疗]
Chirurg. 2006 Apr;77(4):325-34. doi: 10.1007/s00104-006-1177-4.
3
Evolution of surgery for Klatskin tumor demonstrates improved outcome: a single center analysis.肝门部胆管癌手术的进展显示预后改善:一项单中心分析
Tumori. 2014 Nov-Dec;100(6):e250-6. doi: 10.1700/1778.19288.
4
Role of hilar resection in the treatment of hilar cholangiocarcinoma.肝门部切除术在肝门部胆管癌治疗中的作用。
Hepatogastroenterology. 2012 May;59(115):696-700. doi: 10.5754/hge09725.
5
Concomitant Precise Hemihepatectomy to Improve the Efficacy of Surgical Treatment for Hilar Cholangiocarcinoma: Analysis of 38 Cases.同期精准半肝切除术提高肝门部胆管癌外科治疗疗效:38例分析
Hepatogastroenterology. 2014 Jun;61(132):927-32.
6
Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma involving the hepatic hilus versus hilar cholangiocarcinoma after curative-intent resection: Should they be recognized as perihilar cholangiocarcinoma or differentiated?肝门部胆管癌累及肝门部与肝门部胆管癌根治性切除术后的长期预后和预后因素:是否应将其视为肝门周围胆管癌或加以区分?
Eur J Surg Oncol. 2019 Nov;45(11):2173-2179. doi: 10.1016/j.ejso.2019.06.014. Epub 2019 Jun 11.
7
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.肝门部胆管癌切除术:同期肝切除可降低肝内复发率。
Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.
8
Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.肝门部胆管癌的预后因素及长期结局:中国单中心经验
World J Gastroenterol. 2016 Feb 28;22(8):2601-10. doi: 10.3748/wjg.v22.i8.2601.
9
Liver transplantation for hilar cholangiocarcinoma.肝移植治疗肝门部胆管癌。
World J Gastroenterol. 2013 Dec 28;19(48):9209-15. doi: 10.3748/wjg.v19.i48.9209.
10
Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma.术后发病率导致肝门部胆管癌切除术后长期生存率降低。
HPB (Oxford). 2011 Feb;13(2):139-47. doi: 10.1111/j.1477-2574.2010.00262.x. Epub 2010 Dec 7.

引用本文的文献

1
Perihilar cholangiocarcinoma: a surgeon's perspective.肝门部胆管癌:外科医生的视角
ILIVER. 2022 Apr 5;1(1):12-24. doi: 10.1016/j.iliver.2022.03.004. eCollection 2022 Mar.
2
Improved Outcomes Following Resection of Perihilar Cholangiocarcinoma: A 27-Year Experience.肝门部胆管癌切除术后改善的预后:27年经验
Ann Surg Oncol. 2025 Jun;32(6):4352-4362. doi: 10.1245/s10434-025-17075-5. Epub 2025 Feb 25.
3
Dynamic three-dimensional liver volume assessment of liver regeneration in hilar cholangiocarcinoma patients undergoing hemi-hepatectomy.肝门部胆管癌患者半肝切除术后肝再生的动态三维肝脏体积评估
Front Oncol. 2024 Apr 19;14:1375648. doi: 10.3389/fonc.2024.1375648. eCollection 2024.
4
Real-world experience supporting the role of oncologic resection and adjuvant chemotherapy in biliary tract cancers.支持肿瘤切除和辅助化疗在胆道癌中作用的真实世界经验。
Ther Adv Med Oncol. 2024 Apr 15;16:17588359241247008. doi: 10.1177/17588359241247008. eCollection 2024.
5
Modified technique of Hepatojejunostomy for biliary tract reconstruction after resection of tumors affecting the perihilar region: a case series.改良肝肠吻合术在肝门周围肿瘤切除后胆道重建中的应用:病例系列研究。
BMC Surg. 2024 Apr 10;24(1):102. doi: 10.1186/s12893-024-02393-4.
6
Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements.肝门部胆管癌的多学科治疗:指南综述与最新进展
Cancers (Basel). 2023 Dec 20;16(1):30. doi: 10.3390/cancers16010030.
7
A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years.肝门部胆管癌病例系列:一位外科医生20年的经验
Ann Med Surg (Lond). 2021 Jan 22;62:239-243. doi: 10.1016/j.amsu.2021.01.059. eCollection 2021 Feb.
8
Clinical practice of basin-shaped hepaticojejunostomy following hilar resection of stage III/IV hilar cholangiocarcinoma.肝门部胆管癌 III/IV 期切除术后盆式胆肠吻合术的临床实践。
BMC Gastroenterol. 2019 Jun 20;19(1):99. doi: 10.1186/s12876-019-1012-2.
9
Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma.术前高胆红素血症在肝门部胆管癌患者行肝胆切除术中的相关性
J Clin Med. 2019 Apr 5;8(4):458. doi: 10.3390/jcm8040458.
10
Surgery for cholangiocarcinoma.胆管癌的外科治疗。
Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089.

本文引用的文献

1
Liver transplantation for cholangiocarcinoma.肝移植治疗胆管细胞癌。
Transpl Int. 2010 Jul;23(7):692-7. doi: 10.1111/j.1432-2277.2010.01108.x. Epub 2010 May 20.
2
Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.基于吉西他滨的辅助化疗可提高肝门部胆管癌根治性手术后的生存率。
J Gastrointest Surg. 2009 Aug;13(8):1470-9. doi: 10.1007/s11605-009-0900-0. Epub 2009 May 7.
3
Portal vein embolization in hilar cholangiocarcinoma.肝门部胆管癌的门静脉栓塞术
Surg Oncol Clin N Am. 2009 Apr;18(2):257-67, viii. doi: 10.1016/j.soc.2008.12.007.
4
Preoperative biliary drainage before resection for cholangiocarcinoma (Pro).术前胆管引流在胆管癌切除术前(Pro)。
HPB (Oxford). 2008;10(2):130-3. doi: 10.1080/13651820801992666.
5
Survival and an overview of decision-making in patients with cholangiocarcinoma.胆管癌患者的生存情况及决策概述
Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):412-7.
6
Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.肝门部胆管癌切除术:同期肝切除可降低肝内复发率。
Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.
7
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience.肝门部胆管癌的积极手术切除:是否合理?单中心经验的审计
Am J Surg. 2008 Aug;196(2):160-9. doi: 10.1016/j.amjsurg.2007.07.033. Epub 2008 May 7.
8
Surgical management of hilar cholangiocarcinoma: the Nagoya experience.肝门部胆管癌的外科治疗:名古屋经验。
HPB (Oxford). 2005;7(4):259-62. doi: 10.1080/13651820500373010.
9
Cholangiocarcinoma.胆管癌
Clin Liver Dis. 2008 Feb;12(1):131-50, ix. doi: 10.1016/j.cld.2007.11.003.
10
Surgical approach to bismuth Type I and II hilar cholangiocarcinomas: audit of 54 consecutive cases.针对比氏I型和II型肝门部胆管癌的手术方法:对54例连续病例的审计
Ann Surg. 2007 Dec;246(6):1052-7. doi: 10.1097/SLA.0b013e318142d97e.

肝门部胆管癌的外科切除术:经验可提高可切除性。

Surgical resection for hilar cholangiocarcinoma: experience improves resectability.

机构信息

Division of Transplantation, Department of Surgery, University of Louisville, Louisville, KY, USA.

出版信息

HPB (Oxford). 2012 Feb;14(2):142-9. doi: 10.1111/j.1477-2574.2011.00419.x. Epub 2011 Dec 12.

DOI:10.1111/j.1477-2574.2011.00419.x
PMID:22221577
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3277058/
Abstract

OBJECTIVES

In hilar cholangiocarcinoma, resection provides the only opportunity for longterm survival. A US experience of hilar cholangiocarcinoma was examined to determine the effect of clinical experience on negative margin (R0) resection rates.

METHODS

We conducted a retrospective analysis of 110 consecutive hilar cholangiocarcinoma patients presenting over an 18-year period. Analyses were performed using chi-squared, Wilcoxon rank sum and Kaplan-Meier methods, and multivariable Cox and logistic regression modelling.

RESULTS

Of the 110 patients in the cohort, 59.1% were male and 90.9% were White. The median patient age was 64 years. A total of 59 (53.6%) patients underwent resection; 37 of these demonstrated R0. The 30-day mortality rate was 5.1%; the complication rate was 39.0%. The rate of resectability increased over time (36.4% vs. 70.9%; P= 0.001), as did the percentage of R0 resections (10.9% vs. 56.5%; P < 0.001). Of the 59 patients who underwent resection, 23 (39.0%) experienced recurrence. Multivariable Cox regression analysis identified resection margins [hazard ratio (HR) = 4.124 for positive vs. negative; P= 0.002] and type of operation (HR = 5.075 for exploration vs. resection; P= 0.001) as significant to survival.

CONCLUSIONS

Although R0 resection can be achieved in only a minority of patients, these patients have a reasonable chance of longterm survival. The last decade has seen a significant rise in rates of resectability of Klatskin's tumour at specialty centres.

摘要

目的

在肝门部胆管癌中,切除是获得长期生存的唯一机会。本文分析了美国肝门部胆管癌的治疗经验,以明确临床经验对切缘阴性(R0)切除率的影响。

方法

我们对 18 年间收治的 110 例肝门部胆管癌患者进行回顾性分析。采用卡方检验、Wilcoxon 秩和检验和 Kaplan-Meier 方法以及多变量 Cox 和逻辑回归模型进行分析。

结果

该队列中 110 例患者中,59.1%为男性,90.9%为白人。中位患者年龄为 64 岁。共 59 例患者接受了手术切除,其中 37 例为 R0 切除。30 天死亡率为 5.1%,并发症发生率为 39.0%。可切除性的比例随时间增加而增加(36.4% vs. 70.9%,P=0.001),R0 切除率也随之增加(10.9% vs. 56.5%,P<0.001)。59 例行切除术的患者中,23 例(39.0%)复发。多变量 Cox 回归分析显示,切除边缘(阳性 vs. 阴性,HR=4.124,P=0.002)和手术方式(探查术 vs. 切除术,HR=5.075,P=0.001)与生存显著相关。

结论

尽管只有少数患者能够达到 R0 切除,但这些患者仍有获得长期生存的合理机会。在专业中心,近 10 年来 Klatskin 肿瘤的可切除率显著提高。